BCA
CTMX icon

Bay Colony Advisors’s CytomX Therapeutics CTMX Stock Holding History

Bay Colony Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,747
Closed -$34.3K – 505
2025
Q3 		$34.3K Buy
+10,747
New +$24.2K ﹤0.01% 509

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Bay Colony Advisors's CTMX Position: Q4 2025 in Review

Bay Colony Advisors sold out of CytomX Therapeutics (CTMX) in Q4 2025, closing a stake of 10,747 shares — an estimated $34.3K sold.

Bay Colony Advisors first reported a position in CTMX in Q3 2025 and held it in 1 quarter. The position peaked at $34.3K in Q3 2025. 122 funds tracked by Wall St. Rank hold CTMX as of Q4 2025.

  • Bay Colony Advisors reported no remaining CytomX Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Bay Colony Advisors sold 10,747 CytomX Therapeutics shares in Q4 2025, an estimated $34.3K.
  • Bay Colony Advisors first reported a position in CytomX Therapeutics in Q3 2025 and held it in 1 quarter.
  • Bay Colony Advisors's CytomX Therapeutics position peaked at $34.3K in Q3 2025.
  • 122 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2025.

Based on Bay Colony Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.